PubRank

David Bishop-Bailey

Author PubWeight™ 29.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2005 1.77
2 Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2006 1.74
3 Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovasc Res 2011 1.53
4 The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008 1.42
5 The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 2006 1.31
6 Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol 2003 1.28
7 Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 2007 1.22
8 Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J 2005 1.18
9 Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am J Respir Crit Care Med 2010 1.10
10 Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 2005 1.08
11 Analysing the eosinophil cationic protein--a clue to the function of the eosinophil granulocyte. Respir Res 2011 1.07
12 Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 2007 1.05
13 The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo. PLoS One 2009 1.04
14 Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. Exp Physiol 2007 1.02
15 Anti-inflammatory effects of epoxyeicosatrienoic acids. Int J Vasc Med 2012 1.01
16 Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One 2011 0.99
17 Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol 2009 0.99
18 Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol Pharmacol 2003 0.93
19 PPARα-LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status. Biochem J 2011 0.90
20 COX-2 in cardiovascular disease. Arterioscler Thromb Vasc Biol 2006 0.89
21 Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease? PLoS One 2013 0.87
22 Roles of the epoxygenase CYP2J2 in the endothelium. Prostaglandins Other Lipid Mediat 2013 0.85
23 Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB J 2006 0.82
24 Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. J Pharmacol Exp Ther 2004 0.82
25 Dissecting the role of eosinophil cationic protein in upper airway disease. Curr Opin Allergy Clin Immunol 2012 0.81
26 Peroxisome proliferator-activated receptor beta/delta goes vascular. Circ Res 2008 0.79
27 Inflammation and vascular remodeling. Int J Vasc Med 2012 0.78
28 The potential use of the pregnane X receptor in cardiovascular therapy. Expert Rev Cardiovasc Ther 2012 0.77
29 Interactions between CKD and MetS and the Development of CVD. Cardiol Res Pract 2011 0.75